Minimizing the risk of allo-sensitization to optimize the benefit of allogeneic cardiac-derived stem/progenitor cells
Citations Over TimeTop 22% of 2017 papers
Abstract
Allogeneic human cardiac-derived stem/progenitor cells (hCPC) are currently under clinical investigation for cardiac repair. While cellular immune response against allogeneic hCPC could be part of their beneficial-paracrine effects, their humoral immune response remains largely unexplored. Donor-specific HLA antibodies (DSA-HLA-I/DSA-HLA-II), primary elements of antibody-mediated allograft injury, might present an unidentified risk to allogeneic hCPC therapy. Here we established that the binding strength of anti-HLA monoclonal antibodies delineates hCPC proneness to antibody-mediated injury. In vitro modeling of clinical setting demonstrated that specific DSA-HLA-I of high/intermediate binding strength are harmful for hCPC whereas DSA-HLA-II are benign. Furthermore, the Luminex-based solid-phase assays are suitable to predict the DSA-HLA risk to therapeutic hCPC. Our data indicate that screening patient sera for the presence of HLA antibodies is important to provide an immune-educated choice of allogeneic therapeutic cells, minimize the risk of precipitous elimination and promote the allogeneic reparative effects.
Related Papers
- → Can pan-allergens affect the sensitization pattern?(2017)5 cited
- → Risk Factors for Asthma and Other Allergic Diseases in Seasonal Rhinitis(2008)12 cited
- → Age‐dependent induction and maintenance of sensitization to methamphetamine‐induced hyperactivity in mice(1996)5 cited
- → Effect of Chemical Sensitization on Desensitization by Phenosafranine and Discussions on Mechanism of Chemical Sensitization (Reduction Sensitization and Sulfur Sensitization)(1969)
- → Monoclonal Antibody 1C11 Mouse Monoclonal Antibody Against Mortalin(2017)